The GLP-1 obesity pill era is here Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M Tue W Th F 23 December, 2025

Biopharma’s year doesn’t start on January 1. It starts in San Francisco. Join Endpoints for bold conversations with the leaders shaping what's next. Plus, get access to the Endpoints Hub — our premium coworking and meeting space just steps from the action. Reserve your spot now.

spotlight Exclusive: Bristol Myers brings IRA fight to Supreme Court as 'regime of forced sales' is poised to take effect

news Updated: Pfizer discloses patient death in Hympavzi hemophilia trial Novo Nordisk eyes a strong launch with FDA approval of obesity pill

Client Engagement Mgr - Life Sciences Strategy & Intelligence Sedulo Group Remote Analyst – Life Sciences Strategy & Intelligence Sedulo Group Remote Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

Jan 28 11:00am ET How breakthrough RWE is powering a new era of blood cancer research sponsored by Flatiron Jan 22 12:00pm ET Scaling for a New Era: The Rise of Radiopharma sponsored by PharmaLogic

Share your perspective. Endpoints is fielding the next Biopharma Sentiment Index (BPSI), a three-minute survey that distills thousands of industry views into a quarterly benchmark. It’s one of the clearest snapshots of how people inside biopharma see the year ahead. Add your voice today.

endpoints pharma China's new commercial insurance model could broaden access to Alzheimer's drugs To industry’s dismay, CMS presents two Medicare payment demos as part of Trump's MFN plan US accuses six people in scheme to manipulate Olema Oncology's share price

in case you missed it 1. Shionogi to pay $2.5B to acquire one of the only approved ALS drugs 2. Windward pays up to $700M to gain Qyuns bispecific in second China deal of year 3. Ipsen adds to deal spree with ADC from Shanghai biotech Simcere Zaiming 4. Boehringer taps Rectify to create pills for chronic kidney disease 5. AstraZeneca bets up to $2B on Jacobio’s pan-KRAS inhibitor for cancer 6. Aktis Oncology files for IPO to fund Lilly-partnered radiopharma pipeline 7. J&J vows appeal after US jury hits it with record $1.5 billion talc cancer award 8. Your Brain Ages in Five Distinct Stages, New Research Shows